初诊时骨关节炎疾病负担与类风湿关节炎相似,6个月后显著更高
该研究基于Rush大学医学中心风湿科2011至2017年新诊OA与RA患者,在初诊和6个月随访时完成MDHAQ/RAPID3评估。初诊时OA与未使用DMARD的RA患者RAPID3均值无显著差异(范围14.8-16.4,P=0.38);6个月后RA改善显著大于OA(P<0.001),OA的RAPID3高于RA。
要点
- 初诊时OA与未用DMARD的RA患者RAPID3均值无显著差异。
- 6个月后RA的RAPID3改善显著大于OA(P<0.001),OA疾病负担更高。
- MDHAQ/RAPID3可用于跨疾病比较疾病负担。
核心结论
- 初诊时OA与RA患者的MDHAQ/RAPID3评分相似,但6个月后OA患者评分高于RA患者,反映RA治疗更优。
研究设计与样本
- 回顾性分析2011至2017年Rush大学医学中心风湿科新诊OA和RA患者,所有患者在初诊和6个月随访时完成纸质MDHAQ,评分保存为电子健康记录PDF。
- 比较MDHAQ的0-10分物理功能、疼痛、患者总体评估(汇总为RAPID3 0-30分)及其他量表,并按自转诊/医生转诊及RA的DMARD初治/既往DMARD治疗分组。
- 使用t检验和方差分析比较组间差异,并校正年龄、病程、BMI、教育程度和种族。
主要发现
- 与RA患者相比,OA患者年龄、BMI和病程更高。
- 初诊时OA与DMARD初治RA患者(无论自转诊或医生转诊)的RAPID3均值无显著差异(范围14.8-16.4,P=0.38)。
- 初诊时全部OA、DMARD初治RA和既往DMARD治疗RA的RAPID3均值分别为15.0、15.7和15.8(P=0.49)。
- 6个月后三组RAPID3分别改善至13.3、10.3和10.8,RA改善显著大于OA(P<0.001)。
- 大多数自报量表和校正分析中观察到相似结果。
关键数值与推荐
- 初诊时OA与DMARD初治RA患者RAPID3均值范围14.8-16.4(P=0.38)。
- 初诊时全部OA、DMARD初治RA、既往DMARD治疗RA的RAPID3均值分别为15.0、15.7、15.8(P=0.49)。
- 6个月后三组RAPID3分别改善至13.3、10.3、10.8,RA改善显著大于OA(P<0.001)。
临床怎么用
- 在风湿科初诊时,应同等重视OA患者的疾病负担评估,其RAPID3评分可能与RA相当。
- 6个月随访时OA患者疾病负担可能仍高,需关注其治疗不足并优化管理。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze disease burden in osteoarthritis (OA) according to Multidimensional Health Assessment Questionnaire (MDHAQ)/Routine Assessment of Patient Index Data 3 (RAPID3) scores at the initial visit and the 6-month follow-up visit, compared with rheumatoid arthritis (RA) as a benchmark for high disease burden. METHODS: All patients with all diagnoses at the Rush University Medical Center Division of Rheumatology complete a paper MDHAQ at all visits, saved as a PDF in the electronic health record. MDHAQ 0-10 scores for physical function, pain, and patient global assessment (compiled into RAPID3 0-30 scores) and additional scales at the initial and 6-month follow-up visits, for new OA and RA patients seen from 2011 to 2017, were compared. OA and RA patients were classified as self-referred or physician-referred, and RA patients were classified as disease-modifying antirheumatic drug (DMARD)-naive or having prior-DMARD treatment. Patient groups were compared using t-tests and analysis of variance, adjusted for age, disease duration, body mass index (BMI), education, and ethnicity. RESULTS: Compared with RA patients, OA patients had higher age, BMI, and disease duration. At initial visit, the mean RAPID3 did not differ significantly in OA versus DMARD-naive RA patients, whether self- or physician-referred (range 14.8-16.4 [P = 0.38]), or in all OA patients versus DMARD-naive RA patients versus prior-DMARD RA patients (15.0, 15.7, and 15.8, respectively [P = 0.49]). After 6 months, RAPID3 was improved to 13.3, 10.3, and 10.8, respectively, which represented substantially greater improvement in RA patients than OA patients (P < 0.001). Similar results were seen for most self-reported measures and in adjusted analyses. CONCLUSION: MDHAQ/RAPID3 scores are similar in OA and RA patients at the initial visit, but higher in OA patients than in RA patients 6 months later, reflecting superior RA treatments. The same MDHAQ/RAPID3 allows comparisons of disease burdens in different diseases.
引用
- Chua JR, Jamal S, Riad M, et al. Disease Burden in Osteoarthritis Is Similar to That of Rheumatoid Arthritis at Initial Rheumatology Visit and Significantly Greater Six Months Later. Arthritis Rheumatol. 2019. PMID: 30891933. doi:10.1002/art.40869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。